engleski

-

The aim of this research was to examine the efficacy of parenteral administration of azithromycin in the treatment of erysipelas. In the period from January 1, 2001 until August 31, 2001, we examined a total of 42 patients with erysipelas, of whom 10 had facial erysipelas and 32 erysipelas on lower legs and feet. Study inclusion criteria were as follows: hospitalized patients of both sexes older than 18 years of age, fever ł37, 5°C, leukocytosis >10x109/L with neutrophilia, the presence of at least two of the following symptoms: redness, swelling, pruritis, burning, regional lymphangitis/lymphadenitis. Patients with lower extremity varicosity, ulcus cruris, pregnant and lactating women as well as persons who had taken antimicrobial drugs within 48 hours prior to their enrolment were excluded from the study. Azithromycin was administered in dosage of 1x500 mg iv for 3 days followed by additional dose of 1x500 mg for 2 days. Clinical efficacy was evaluated 5 days after the beginning of treatment in the following manner: cure - disappearance of clinical symptoms present at the beginning of treatment, marked decrease of leukocytes number ; improvement - less clinical symptoms present than at the beginning of treatment ; failure - patients in whom 60 hours after the start of therapy fever hasn't lowered to Ł37, 5°C and with no tendency of leukocytes decrease compared with laboratory results obtained at the beginning of therapy, as well as patients with persistent or recurrent clinical symptoms 5 days after the beginning of treatment. Treatment results: cure in 36 (85.43%), improvement in 2 (7.28%), and failure in 2 (7.28%) patients. During the administration of therapy there were no adverse events recorded. In conclusion, parenteral administration of azithromycin proved efficient in the treatment of erysipelas.

-

nije evidentirano